Remove Clinical Trials Remove Media Remove Safety
article thumbnail

Press Release: Mydecine Secures Financing and Provides Company Update on Clinical Trials, Drug Development and Technology Initiatives

Cannabis Law Report

The Financing will allow the Company to continue progressing its R&D, clinical trials and technology initiatives. “I I’m proud of our accomplishments to date and look forward to kicking off multiple clinical trials in early 2022,” said CEO, Josh Bartch. DENVER, Dec.

article thumbnail

Cybin Announces Closing of Overnight Marketed Public Offering of Common Shares and Exercise of Over-Allotment Option

Cannabis Law Report

Vigorous scientific research and clinical trials are needed. Cybin has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that Cybin verified such in clinical trials or that Cybin will complete such trials.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Press Release: COMPASS Pathways plc financial results second quarter 2021 – Reminds us of that rich people’s festival in the desert

Cannabis Law Report

Phase IIb clinical trial of COMP360 psilocybin therapy for TRD close to completion. Danielle Schlosser PhD appointed Senior Vice-President, Clinical Innovation, to lead therapist research and training, bringing her clinical experience in behavioural health and expertise in digital health innovation. Business highlights.

article thumbnail

Mydecine Expands Portfolio of Novel Molecules Filing New Patent for MDMA-like Compounds

Cannabis Law Report

The groundbreaking progress that we’ve seen from the Multidisciplinary Association for Psychedelic Studies (MAPS) in its Phase 3 clinical trials of MDMA-assisted psychotherapy for Post-Traumatic Stress Disorder (PTSD), including receiving Breakthrough Therapy Designation from the Food and Drug Administration (FDA), shows great promise to date.

article thumbnail

Virpax Announces Clinical Trial Site in Canada for First in Human Study of Epoladerm™ for Pain Associated with Osteoarthritis of the Knee

Cannabis Law Report

(“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, signed a clinical trial agreement with Altasciences Company, Inc., Media: Laura Radocaj. Chipman, CPA. Chief Financial Officer. cchipman@virpaxpharma.com 610-727-4597.

article thumbnail

‘Too costly, not enough evidence it works’, says UK in blow to cannabis campaigners

Cannabis Law Report

In November 2018, the legal status of cannabis was changed to allow specialist clinicians to legally prescribe cannabis-derived medicinal products to patients with an exceptional clinical need, following a high-profile media campaign. This would answer questions about safety and efficacy, they said.

article thumbnail

MyMD Pharmaceuticals Announces New Data from Comparative Study on Lead Compound MYMD-1

Cannabis Law Report

We remain encouraged as we continue our evaluations of MYMD-1 for efficacy and safety – especially as studies continue to suggest we may be able to address many of the concerns that are associated with the current drugs on the market today in these disease areas.”. Media Contact: Will Johnson. Investor Contact: Robert Schatz.